A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Obesity is a chronic metabolic disease that can increase the risk of developing several severe comorbidities including Type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, and non-alcoholic fatty liver disease.

Huge Unmet Medical Needs

• About 650 million people are living with obesity and a lot more living with overweight

• Only about 2% of the 650 million people are treated with anti-obesity medication (AOM)

• Current approved medicines either come with serious side effects or need frequent injections, leading to poor adherence and persistence with AOMs

MoA: GDF15/GFRAL is a Promising Target for Tackling Obesity

• Growth differentiation factor 15 (GDF15) binds to its specific receptor GFRAL in the area postrema and nucleus

• The GDF15-GFRAL complex activates the tyrosine kinase receptor RET, which reduces energy in take and ultimately could lead to weight loss

Competitive Landscape

With innovative molecular design, the candidate has the potential to be a monthly dosing AOM

Advantages of product:

• The Candidate is a novel long-acting GDF15 analog for obesity treatment with the potential to achieve once-monthly dosing, differentiating from other once-weekly GDF15 analogs or GLP-1 based AOMs
• The candidate has better and long-lasting body weight reduction efficacy than reference Fc-GDF15
• The candidate has superior body weight reduction efficacy to Semaglutide with much lesser dosing frequency in ob/ob mice model

Long-acting Efficacy Proof of Concept

• Single injection of candidate results in body weight loss lasting for a month in mice model

• The candidate has better and long-lasting body weight reduction efficacy than reference Fc-GDF15

Development Status： IND ready

Summary: Superior body weight reduction with lesser dosing frequency

If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review.

Thank you very much!